Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models

INTERNATIONAL JOURNAL OF ONCOLOGY 46 巻 1801-1809 頁 2015 発行
アクセス数 : 2360
ダウンロード数 : 80

今月のアクセス数 : 64
今月のダウンロード数 : 1
ファイル情報(添付)
タイトル
Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models
著者
足立 康二
OKADA MASAHIRO
熊野御堂 慧
TANAKA JUNKO
収録物名
INTERNATIONAL JOURNAL OF ONCOLOGY
46
開始ページ 1801
終了ページ 1809
収録物識別子
ISSN 1019-6439
内容記述
その他
Multiple myeloma is a malignant proliferative disease of plasma cells in the bone marrow and remains largely incurable. Cotylenin A, a fusicoccane diterpene glycoside with a complex sugar moiety, was isolated as a plant-growth regulator. Cotylenin A has been shown to inhibit the growth of various cancer cells. Herein, we examined the anti-myeloma effects of cotylenin A using five human myeloma cell lines (RPMI-8226, KMS-11, KMS-26, KMS-12 PE and KMS-12 BM) and xenografts in immunodeficient mice. Cotylenin A and vincristine synergistically inhibited the growth and induced apoptosis in myeloma cells. While other microtubule-disturbing agents also showed co-operative effects with cotylenin A, other anticancer agents, such as doxorubicin, cisplatin, camptothecin, methotrexate, gemcitabine and 5-fluorouracil, did not show such co-operation with cotylenin A. These differences might be attributed to the effects on autophagic responses. Combined treatment with cotylenin A and vincristine induced autophagy (formation of LC3-II and degradation of p62 protein). However, doxorubicin did not enhance the autophagy induced by cotylenin A. A colony-forming assay indicated that the combined treatment with cotylenin A and vincristine more effectively suppressed the formation of large colonies, which have higher self-renewal activity than vincristine alone. Expression of pluripotency-associated transcription factor Sox2 mRNA in RPMI-8226 myeloma cells was significantly suppressed by treatment with cotylenin A. Combined treatment with cotylenin A and vincristine significantly inhibited the growth of KMS-26 myeloma cells as xenografts. Our results suggest that the combination of cotylenin A and vincristine may have therapeutic value. Recently, it was reported that cotylenin A modulates the 14-3-3 intracellular signaling pathway. The 14-3-3 proteins may be novel targets in treating myeloma. However, our study could not explain how the sensitization to vincristine is related to the effects of cotylenin A on the
主題
myeloma cell ( その他)
cotylenin A ( その他)
vincristine ( その他)
stemness ( その他)
xenograft ( その他)
言語
英語
資源タイプ 学術雑誌論文
出版者
Spandidos Publications
発行日 2015
出版タイプ Version of Record(出版社版。早期公開を含む)
アクセス権 オープンアクセス
関連情報
[DOI] 10.3892/ijo.2015.2882